# OnCo record zelluna (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/zelluna/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "zelluna" ;
  schema:name "Zelluna"@en ;
  schema:alternateName "Zelluna ASA"@en, "Zelluna Immunotherapy AS"@en ;
  schema:description "Zelluna is a Norwegian company that gives natural killer cells, a type of immune cell, a T-cell receptor so they can recognise a marker found inside many solid tumours. Its first product, ZI-MA4-1, is in an early trial."@en ;
  schema:url <https://onco.cc/companies/zelluna/>, <https://zelluna.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://zelluna.com/>, <https://zelluna.com/about-zelluna>, <https://zelluna.com/investors/share-information>, <https://clinicaltrials.gov/study/NCT07613723> ;
  schema:addressCountry "NO" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/lung-squamous-cell-carcinoma/>, <https://onco.cc/cancers/synovial-sarcoma/>, <https://onco.cc/cancers/head-and-neck/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/nk-cell-therapy/>, <https://onco.cc/technologies/tcr-t/>, <https://onco.cc/technologies/allogeneic-cell-therapy/> ;
  onco:targets <https://onco.cc/targets/mage-a4/> .